Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Novartis: Positive Phase III results for MS drug

Written by: | no-reply@reuters.com | Dated: Thursday, August 25th, 2016

 

Novartis AG said a late-stage study showed its oral, once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.

The Phase III EXPAND study, the largest randomized, controlled study in secondary progressive multiple sclerosis (SPMS) to date, met its primary endpoint, compared with placebo, the Swiss drugmaker said in a statement on Thursday.

“SPMS is a particularly disabling form of MS, and there is a need for effective treatment options to help delay disability progression in those living with the condition,” Vasant Narasimhan, global head of drug development and chief medical Officer for Novartis, said in the statement.

(Reporting by Silke Koltrowitz)

 

Source: Reuters Health

http://www.reuters.com/article/us-novartis-siponimod-idUSKCN1100CU

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom